We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+47.39%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2B
AUM Growth
+$348M
Cap. Flow
+$158M
Cap. Flow %
7.89%
Top 10 Hldgs %
49.36%
Holding
84
New
15
Increased
23
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$49.2M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.6M
3
UTHR icon
United Therapeutics
UTHR
+$39.8M
4
CYTK icon
Cytokinetics
CYTK
+$36.5M
5
ABVX
Abivax
ABVX
+$32.5M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$68.5M
2
RNAM
Avidity Biosciences
RNAM
+$36.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$27.8M
5
ERAS icon
Erasca
ERAS
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.96%
2 Miscellaneous 3.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
76
Kymera Therapeutics
KYMR
$9.82B
– –
-130,000
Closed -$10.1M
MREO
77
Mereo BioPharma
MREO
$40.3M
– –
-1,850,000
Closed -$771K
NGNE icon
78
Neurogene
NGNE
$732M
– –
-195,000
Closed -$4.02M
NRIX icon
79
Nurix Therapeutics
NRIX
$2.72B
– –
-500,000
Closed -$9.48M
NUVB.WS
80
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-66,666
Closed -$22K
QURE icon
81
uniQure
QURE
$3.38B
– –
-675,000
Closed -$16.2M
RCUS icon
82
CALL
Arcus Biosciences
RCUS
$3.72B
– –
-1,050,000
Closed -$25M
RNAM
83
DELISTED
Avidity Biosciences
RNAM
– –
-500,000
Closed -$36.1M
RVMD icon
84
CALL
Revolution Medicines
RVMD
$44.6B
– –
-1,000,000
Closed -$79.7M
1 2 3
4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q1 2026 Portfolio in Review

As of Q1 2026, Logos Global Management held 84 positions worth $2B, up 21% from $1.65B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Logos Global Management deployed $158M of net new capital in Q1 2026, opening 15 new positions and adding to 23 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 85,000 shares worth $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $27.8M trimmed.

  • Logos Global Management's largest Q1 2026 buy was Madrigal Pharmaceuticals: 85,000 shares worth $44.5M.
  • Logos Global Management added most to Centessa Pharmaceuticals in Q1 2026, an estimated $49.2M increase.
  • Logos Global Management's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $27.8M.
  • Logos Global Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $68.5M.
  • Logos Global Management's ten largest holdings make up 49% of its $2B portfolio in Q1 2026.
  • Logos Global Management opened 15 new positions and closed 18 in Q1 2026.
  • Logos Global Management's portfolio value rose 21% quarter-over-quarter to $2B.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.